Surgical treatment of liver metastases from kidney cancer: a systematic review

ANZ J Surg. 2019 Jan;89(1-2):32-37. doi: 10.1111/ans.15000. Epub 2019 Jan 26.

Abstract

Background: Liver metastases are present in 20.3% of metastatic kidney cancers. The aim of this literature review was to assess the efficacy of surgical treatment for hepatic metastasis from kidney cancer.

Methods: An extended web search of the literature was independently performed in March 2018 by two authors according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.

Results: Through electronic searches, we identified 935 potentially relevant citations. Thirteen articles were finally included in the systematic review. Median survival after resection ranged from 15 to 142 months while the 1-, 3- and 5-year overall survival ranged from 69% to 100%, 26% to 83.3% and 0% to 62%, respectively. Median disease-free survival ranged from 7.2 to 27 months.

Conclusion: Surgical treatment of hepatic metastases is performed in approximately 1% of patients with liver metastases and in select patients may be potentially curative. Surgical resection of liver metastases from kidney cancer represents a valid option for selected patients with metastatic renal cancer.

Keywords: hepatic resection; kidney cancer; liver metastases; liver surgery; non-colorectal liver metastases.

Publication types

  • Systematic Review

MeSH terms

  • Aged
  • Colorectal Neoplasms / surgery
  • Disease-Free Survival
  • Female
  • Hepatectomy / methods
  • Hepatectomy / mortality*
  • Humans
  • Kidney Neoplasms / complications
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / secondary*
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / surgery*
  • Lymphatic Metastasis / pathology
  • Male
  • Middle Aged
  • Observational Studies as Topic
  • Survival Analysis